Could an anomaly in the developing brain explain motor difficulties occurring decades later in people with rare movement ...
Columbia University Medical Center-led research reports that home high-intensity aerobic training improved ataxia symptoms, fatigue, and aerobic fitness more than dose-matched home balance training in ...
"The findings in these abstracts are exciting for their potential to change the long-term outlook for individuals with Friedreich's ataxia," said Dr. Liana Rosenthal, Associate Pr ...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Biogen Inc. has launched the BRAVE study, a global Phase 3 clinical trial aimed at assessing the efficacy and safety of omaveloxolone in children aged 2 to under 16 years with Friedreich ataxia (FA), ...
A backpack equipped with gyroscopes shows promise as a balance aid for people with the movement disorder ataxia and could one ...
Zacks Investment Research on MSN
Biogen Gets EU Nod for First Postpartum Depression Drug
Biogen BIIB announced that the European Commission (“EC”) has approved Zurzuvae (zuranolone) to treat postpartum depression (PPD) in adults after childbirth. Following this approval, Zurzuvae became ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback